Notifications
Clear all
Quality Assurance (QA) & Regulatory Affairs
2
Posts
2
Users
0
Reactions
108
Views
Topic starter
What is the most common weakness regulators see in CMC sections for biologics?
Posted : 03/04/2026 11:40 am
Insufficient demonstration of process consistency and product comparability across development stages. Changes in cell line, scale, or process can affect product quality. Regulators expect robust comparability studies supported by analytical data and scientific justification.
Please visit BioQC for additional insights on Quality Assurance (QA) and regulatory affairs: https://bio-qc.com/category/quality-assurance-qa-regulatory-affairs/
Posted : 17/04/2026 11:43 am
Share:
Advertisement
Advertisement
Advertisement